Oncology Pharma
Year End Review and Outlook
SAN
FRANCISCO, CA -- December 9, 2021 -- InvestorsHub NewsWire
-- Oncology Pharma Inc. (OTC PINK: ONPH) - Oncology Pharma, Inc. ("The
Company") and its Chief Executive are pleased to give a year end
update and provide an outlook for what to look for in the coming
months and year ahead. The Company is proud of
the progress it has made this past year including the addition of
a
renownrenowned Chairman to the Scientific
Advisory Board, retaining a PCAOB audit firm, commencingfirm, commencing financing and work on drug
research and studies with a highly experienced team as further
described below. The Company has further
signed additional licensing agreements throughout the year that it
believes will enhance the growth of the Company. It looks forward to
continuing, expanding and accelerating the work in the coming
year.
Oncology
Pharma, Inc. is a pioneering oncology company dedicated to
providing the financing and the tools to license, develop,
manufacture, and commercialize therapeutics. Over the past several
years the Company has assembled a team of executives and advisors
with proven multi-disciplinary expertise in the fields of oncology
and therapeutics with leadership to identify, negotiate and
amalgamate "best in class" research, technologies, therapeutics and
delivery mechanisms that are synergistic and collaborative.
As stated before, the
Company's goal is to create value, reduce costs and increase the
speed of regulatory approval and commercialization of effective and
safer cancer drugs.
Oncology
Pharma's strategy centers on progressing its licensed products
through initial phases of development and finding the appropriate
path to commercial success and value creation for its
stakeholders. The Company has
specifically chosen during these initial phases to focus on
pediatrics and the potential orphan drug designation, for which the
Company is currently working towards submitting its first
application. The capital outlay is
projected to be significantly lower than traditional drug
development programs and there is a high need for improved
therapies for patients with rare cancers with the potential for
Oncology Pharma to positively impact these patients
worldwide. It is the Company's
position that what it is pursuing is groundbreaking and that the
pediatric market has been underserved by big pharma, which may
allow for significant developments in this field and give the
potential for the Company to stand out amongst its
peers.
As stated in
Oncology Pharma's previous press release, the initial drug product
being developed is a nanoemulsion of dactinomycin.
Dactinomycin was approved
by the FDA more than 50 years ago but has been limited in its
utility due to severe toxic side-effects at effective doses.
The Company believes the
novel formulation currently in development can overcome this
limitation by creating a safer and potentially more effective drug
formulation. This formulation may also
enable greater accumulation of the drug at the tumor site,
potentially increasing its tumor-kill effectiveness while
simultaneously sparing healthy tissues.
Studies and
research have commenced. Initial feasibility work
for this proprietary nanoemulsion of dactinomycin is currently
underway. It is the Company's belief
that this delivery will have broad and far-ranging applications
beyond oncology. The goal is to move this
process into the clinical studies phase as our current research and
studies will permit.
Oncology
Pharma is also in the midst of finalizing all necessary steps to
complete its audit after it has retained its PCAOB qualified
auditors as disclosed in the press release on October 12,
2021. The Company expects this
process to be completed in the coming weeks. If successful, this would
make progress towards the goal of being able to complete an
application to uplist to the Capital Markets Tier of
NASDAQ.
During this
past year Oncology Pharma has also signed license agreements with
Regen BioPharma, Inc. for its small molecule and for the mRNA
technology to address colon cancer and pancreatic
cancer. It is the Company's intent
that in the beginning of next year it will further engage with our
team to advance these licenses along the same path as we have with
the nanoemulsion of dactinomycin.
The Company is
also in the midst of advancing its commitment to Ribeira Solutions'
Connect2Med patient engagement platform and retention
technology. Connect2Med provides a
motivating trial experience through increased engagement and easy
to use communication tools. They have access to a
dedicated trial specific portal (patient facing app), where they
can perform functions like eDiary, ePRO and telehealth visits. The
platform is FHIR compatible and easily integrates with EHR, CTMS,
CRM from major vendors in the industry. Patients' workflow can be
automated through a set of digital workflows, with automated
interventions and escalation when needed. Sites and CROs can post
upcoming trials in a public space for all to see, boosting public
awareness through social sharing. Site owners and Sponsors
have access to impactful data, metrics and reports that allow them
to make strategic decisions to improve retention, growth,
performance, satisfaction and ROI.
Oncology
Pharma has been able to pursue multiple avenues and maintain focus
throughout 2021. The Company expects to
continue this work and pursue developments through its engaged
relationships and license agreements, while seeking value for its
stakeholders. Additional information
will be provided as it becomes available.
ABOUT
ONCOLOGY PHARMA, INC.
ONCOLOGY
PHARMA, INC. (OTC PINK:ONPH) (the 'Company') is currently
engaging in research and development of therapeutics for oncology
and prides itself for having a world-class Advisory Board that
keeps the Company in the forefront of developing technologies in
cancer research, biotechnology, and healthcare.
FORWARD
LOOKING STATEMENTS
Certain of the
matters discussed in this announcement contain forward-looking
statements that involve material risks to and uncertainties in the
Company's business that may cause actual results to differ
materially from those anticipated by the statements made herein.
Such risks and uncertainties include risks related to licensing
arrangements and joint ventures, including the need to negotiate
the definitive agreements for the relationships; possible failure
to realize anticipated benefits of business relationships, and
costs of providing funding to these business relationships. Other
risks and uncertainties relating to the Company include, among
other things, current negative operating cash flows and a need for
additional funding to finance our operating plan; the terms of any
further financing, which may be highly dilutive and may include
onerous terms; unexpected costs and operating deficits, and lower
than expected sales and revenues; uncertain willingness and ability
of customers to adopt new technologies and other factors that may
affect further market acceptance; adverse economic conditions;
adverse results of any legal proceedings; the volatility of our
operating results and financial condition; inability to attract or
retain qualified senior management personnel, including sales and
marketing personnel; our ability to establish and maintain the
proprietary nature of our technology through the patent process, as
well as our ability to possibly license from others patents and
patent applications necessary to develop products; the Company's
ability to implement its long range business plan for various
applications of its technology; the Company's ability to enter into
agreements with any necessary marketing and/or distribution
partners and with any strategic or joint venture partners; the
impact of competition; the obtaining and maintenance of any
necessary regulatory clearances applicable to applications of the
Company's technology; management of growth; and, other risks and
uncertainties. This is not a solicitation to buy or sell securities
and does not purport to be an analysis of the Company's financial
position.
CONTACTS:
For additional
information, please contact the Oncology Pharma at:
One Sansome
Street, Suite 3500
San Francisco,
CA 94104
Phone:
415-869-1038
Fax:
415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com
SOURCE: Oncology
Pharma Inc.
Oncology Pharma (CE) (USOTC:ONPH)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Oncology Pharma (CE) (USOTC:ONPH)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
